Cell Death Differ: EZH2 R342 methylation modification promotes breast cancer metastasis.

EZH2 is a key histoprotein methyl transferase and EMT-inducing factor that previous studies have found to be expressed in a variety of cancers, including breast cancer, and is an important cancer-causing gene.
EZH2 is able to catalyz the trimethylation modification (H3K27me3) of lysine 3 through its SET domain and inhibit transcription of its target gene, ultimately promoting the EMT (endothoste-interstate transformation) process of cancer cells and tumor metastasis.
the molecular mechanism of EZH2 disorder in cancer has yet to be studied.
study, researchers found that the R342 bits of EZH2 were able to be asymmetrically modified by PRZH1 (meR342-EZH2).
and meR342-EZH2 inhibit the phosphorylation modification of CDK1 to T345 and T487 bits, thereby reducing the EZH2 ubibinization process induced by E3 connective enzyme TRAF6.
researchers also found that meR342-EZH2 can lead to lower levels of target gene expression in EZH2 and improve EMT processes, cell invasion, and tumor metastasis in breast cancer cells.
, there was a positive correlation between the expression levels of PRMT1, meR342-EZH2 and EZH2 in breast cancer tissue.
high levels of meR342-EZH2 also eventually corresponded to a poor clinical prognostic prognosticity in breast cancer patients.
, the results provide a new diagnostic target and potential therapeutic target for breast cancer metastasis.
.